The part used differs, and so does the kind of organism. Trametes versicolor, named Coriolus versicolor through most of the older literature, fruits as thin banded fans on dead hardwood, and that fan is the reproductive structure. Inonotus obliquus fruits only briefly, under the bark of a dying birch, so the black lump taken as chaga is sterile tissue: hyphae grown through the wood of the host tree.
The more consequential difference is which material was studied. Turkey tail’s trial record does not belong to turkey tail as a shop ingredient. It belongs to PSK, a protein-bound polysaccharide prepared by one manufacturer from a defined strain, licensed in Japan and given at around 3 g a day alongside chemotherapy since the mid-1970s. PSP is a related preparation from another strain in China, differing in sugar composition.
Chaga has no counterpart to either of those. No licensed preparation, no defined strain behind a clinical programme, no randomised trial. What the chaga literature does contain is oxalate, at levels behind three published case reports of kidney damage, all three requiring haemodialysis, with renal function recovering in only one.
This pair is where the polysaccharide warning bites hardest. Beta-glucan is a difference rather than a direct reading: total glucan is measured, alpha-glucan is measured, and beta-glucan is what remains, because starch reads as alpha-glucan. In liquid-fermented biomass of Trametes versicolor and two other species, total glucan came to 76.15 to 80.45 percent of dry weight at an alpha to beta ratio of 3.22 to 7.26.
The authors put it plainly. Those biomasses differ from fruiting bodies and mycelium chiefly by higher total and alpha-glucan content and lower beta-glucan content. An 80 percent glucan headline is therefore consistent with a modest beta-glucan figure, so the only question is which glucan was read.
Chaga’s variable is solvent rather than substrate. Subcritical water at 200 degrees Celsius drew total glucan of 20.4 and 20.9 g per 100 g out of two chaga samples, up to 20 times the beta-glucan other techniques managed, where 96 percent ethanol under microwave or ultrasound returned 0.62 to 1.13 g per 100 g. Water is also the point for turkey tail: PSK and PSP are water extracted protein-bound polysaccharides.
The turkey tail result belongs to PSK, a licensed preparation given with chemotherapy around cancer surgery, in trials Cochrane rates low to very low certainty. Nothing in it describes a shelf capsule, whose whole human record is a 9-person dose escalation.
Read the turkey tail evidence narrowly before it guides a purchase. It attaches to PSK at around 3 g a day with chemotherapy after cancer surgery, and Cochrane rates it low certainty even there. A shelf capsule is not that preparation, so what to expect from one is unknown. Chaga has no trial and three kidney injury case reports, so the comparison is not which performs better but which one has a documented hazard. Avoid chaga with kidney stones, and raise either mushroom with an oncology team rather than self-prescribing.
Nothing about treating anything. Regulation (EC) 1924/2006 as it applies in Great Britain permits only health claims on the authorised list, and no mushroom claim is on it. The authorised beta-glucan entries name oats, oat bran, barley and barley bran at 3 g a day, for blood cholesterol, and do not extend to mushroom beta-glucans. PSK’s licence sits in Japan and has no standing here, so describing a turkey tail food supplement in cancer terms is unlawful in Great Britain, however the Japanese trials read.
On chaga the question is safety. Analysis of chaga powder in one case report returned 14 g of oxalate per 100 g. The three published nephropathy reports, all three requiring haemodialysis and with renal function recovering in only one, describe a man who went from 3 g to 9 g a day across 5 years, a woman on 4 to 5 teaspoons a day for 6 months, and a man on 10 to 15 g a day with 500 mg of vitamin C whose nephrotic syndrome with calcium oxalate crystals on biopsy needed high-dose steroids before kidney function recovered. Chaga is a poor choice with stones or reduced kidney function.
Turkey tail’s record is narrow rather than reassuring: a phase 1 trial logged 9 adverse events in 9 women at up to 9 g daily. Concentrated fungal extracts can fall within Regulation (EU) 2015/2283 on novel foods as it applies in Great Britain. Endoca’s CBD products are on the FSA public list, which logs applications rather than approvals, under advice of 10 mg a day at most.
Every Endoca mushroom extract is backed by a certificate of analysis, with pesticide, heavy metal and mycotoxin screening to GMP standards and third party verification. Neither certificate states a beta-glucan percentage, so neither shows how much of a declared polysaccharide is beta rather than alpha, and neither states oxalate. Those two readings are what this comparison depends on. Endoca works from its own farm, own land and own extraction, since 2010.
No. PSK, also called krestin, is a protein-bound polysaccharide prepared from a defined strain by a single manufacturer and licensed in Japan as a cancer adjunct. PSP is made in China from another strain to a different specification. A turkey tail capsule is neither.
PSK. A Cochrane review identified 7 randomised trials in 1,569 colorectal cancer patients, 6 in Japan and 1 in China, using PSK with chemotherapy generally after curative resection and in one study beforehand. Five-year survival was higher in 3 of those studies, covering 1,094 participants.
None. No randomised controlled trial of any chaga preparation has been published for any outcome. The published human record is three case reports of oxalate nephropathy, all three requiring haemodialysis, with renal function recovering in only one, after powder taken for months to years.
Glucan includes alpha-glucan, which is mostly starch. Liquid-fermented Trametes versicolor biomass measured 76 to 80 percent total glucan at an alpha to beta ratio of 3.22 to 7.26, and its authors recorded lower beta-glucan in that biomass than in fruiting bodies.
Pilkington K, Wieland LS, Teng L, Jin XY, Storey D, Liu JP. Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with colorectal cancer. Cochrane Database Syst Rev. 2022;11:CD012053.
Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007;56(6):905-911.
Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H, Ohashi Y. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomised controlled clinical trials. Cancer Immunol Immunother. 2006;55(4):404-411.
Torkelson CJ, Sweet E, Martzen MR, Sasagawa M, Wenner CA, Gay J, Putiri A, Standish LJ. Phase 1 clinical trial of Trametes versicolor in women with breast cancer. ISRN Oncol. 2012;2012:251632.
Araujo-Rodrigues H, Amorim M, Sousa C, Salsinha AS, Marcal S, de Freitas V, Relvas JB, Tavaria FK, Pintado ME. Chemical composition of Trametes versicolor, Hericium erinaceus, and Pleurotus ostreatus mushroom biomass: deciphering their rich alpha-glucan composition and nutritional value. J Food Compost Anal. 2025;143.
Jedrzejewski T, Pawlikowska M, Sobocinska J, Wrotek S. COVID-19 and cancer diseases: the potential of Coriolus versicolor mushroom to combat global health challenges. Int J Mol Sci. 2023;24(5):4864.
Lazic V, Lazic V, Klaus A, Kozarski M, Doroski A, Tosti T, Simic S, Vunduk J. The effect of green extraction technologies on the chemical composition of medicinal chaga mushroom extracts. J Fungi (Basel). 2024;10(3):225.
Lee S, Lee HY, Park Y, Ko EJ, Ban TH, Chung BH, Lee HS, Yang CW. Development of end stage renal disease after long-term ingestion of chaga mushroom: case report and review of literature. J Korean Med Sci. 2020;35(19):e122.
Kikuchi Y, Seta K, Ogawa Y, Takayama T, Nagata M, Taguchi T, Yahata K. Chaga mushroom-induced oxalate nephropathy. Clin Nephrol. 2014;81(6):440-444.
Kwon O, Kim Y, Paek JH, Park WY, Han S, Sin H, Jin K. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: a case report. Medicine (Baltimore). 2022;101(10):e28997.
Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods, Annex, beta-glucans entries, as it applies in Great Britain.
Last reviewed 1 October 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.